N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Hartmann, Olivier; Michon, Jean; Frappaz, Didier; Coze, Carole; Chastagner, Pascal; Baranzelli, M. C.; Plantaz, Dominique; Avet-Loiseau, Hervé; Bénard, Jean; Delattre, Olivier; Favrot, M.; Peyroulet, M C; Thyss, Antoine; Pérel, Yves; Bergeron, Christophe; Courbon-Collet, B; Vannier, J. P.; Lemerle, J; Santini, Daniele

doi:10.1200/jco.1997.15.3.1171

Cited by 168 publications

(111 citation statements)

References 40 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…These original ®ndings have generally been con®rmed in subsequent studies (Combaret et al, 1996;Rubie et al, 1997;Tsuda et al, 1997). Overall, N-MYC ampli®cation remains the most widely accepted predictive parameter of long-term, disease-free survival.…”

Section: Neuroblastoma (Nbl)mentioning

confidence: 86%

MYC oncogenes and human neoplastic disease

1999

View full text Add to dashboard Cite

c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we ®rst summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite di erent roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in speci®c neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which signi®cant and con®rmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.

show abstract

Section: Neuroblastoma (Nbl)mentioning

confidence: 86%

MYC oncogenes and human neoplastic disease

1999

View full text Add to dashboard Cite

show abstract

“…Although most of the cases detected by the MSPN had biologically favourable factors, such as nodeletion of 1p and low expression of the TRK-A gene, some cases with unfavourable prognostic factors have been reported (Matsunaga et al, 2000;Tajiri et al, 2001). MYCN is one of the most important prognostic factors in NB (Rubie et al, 1997;Tonini et al, 1997). How MYCN is related to the prognosis and clinical features of infantile cases, especially those discovered by MSPN, is not clear.…”

Section: Discussionmentioning

confidence: 99%

MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening

et al. 2006

View full text Add to dashboard Cite

MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three groups (99, 89 and 53%, respectively) were significantly different (Po0.001), indicating that MYCN copy number correlates with the prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs; Po0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin than non-amplified patients (P ¼ 0.049, P ¼ 0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is indispensable.

show abstract

“…AURKA stabilizes the MYCN protein through a direct physical interaction and interferes. MYCN amplification is another feature often noticed in aggressive neuroblastomas and is a strong marker of poor prognosis (Rubie et al, 1997). MYCN gain has recently been observed in about 6-8% of neuroblastomas MYCN showing a poor survival probability is highly amplified in about 20% of neuroblastoma patients (Spitz et al, 2004).…”

Section: Chromosome Imbalances and Alterations Of Aurka And Mycn Genementioning

confidence: 99%

Chromosome Imbalances and Alterations of AURKA and MYCN Genes in Children with Neuroblastoma

Yılmaz¹,

Demırhan²,

Erdoğan³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Neuroblastoma (NB), like most human cancers, is characterized by genomic instability, manifested at the chromosomal level as allelic gain, loss or rearrangement. Genetics methods, as well as conventional and molecular cytogenetics may provide valuable clues for the identification of target loci and successful search for major genes in neuroblastoma. We aimed to investigate AURKA and MYCN gene rearrangements and the chromosomal aberrations (CAs) to determine the prognosis of neuroblastoma. Methods: We performed cytogenetic analysis by G-banding in 25 cases [11 girls (44%) and 14 boys (66%)] and in 25 controls. Fluorescence in situ hybridization (FISH) with AURKA and MYCN gene probes was also used on interphase nuclei to screen for alterations. Results: Some 18.4% of patient cells exhibited CAs., with a significant difference between patient and control groups in the frequencies (P<0.0001). Some 72% of the cells had structural aberrations, and only 28% had numerical chnages in patients. Structural aberrations consisted of deletions, translocations, breaks and fragility in various chromosomes, 84% and 52% of the patients having deletions and translocations, respectively. Among these expressed CAs, there was a higher frequency at 1q21, 1q32, 2q21, 2q31, 2p24, 4q31, 9q11, 9q22, 13q14, 14q11.2, 14q24, and

show abstract

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Cited by 168 publications

References 40 publications

MYC oncogenes and human neoplastic disease

MYC oncogenes and human neoplastic disease

MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening

Chromosome Imbalances and Alterations of AURKA and MYCN Genes in Children with Neuroblastoma

Contact Info

Product

Resources

About